LUMINA Phase III Study Assessing the Efficacy and Safety of Intravitreal Injections of 440 ug DE-109 Sirolimus for the Treatment of Active, Non-Infectious Uveitis of the Posterior Segment of the Eye
Non Infectious Uveitis

About this trial
This is an interventional treatment trial for Non Infectious Uveitis
Eligibility Criteria
Inclusion Criteria:
Non-Infectious Active Uveitis of the Posterior Segment
Exclusion Criteria:
Females who are pregnant, nursing, or planning a pregnancy Confirmed or suspected infectious uveitis
Sites / Locations
- Arizona Retina & Vitreous Consultants
- Retina-Vitreous Associates Medical Group
- Kaiser Permanente Medical Center
- USC Roski Eye Institute
- Byers Eye Institute at Stanford
- California Eye Specialist Medical Group, Inc.
- Colorado Retina Associates
- Retina Vitreous Associates of Florida
- University of South Florida Eye Institute
- Emory Eye Center
- Marietta Eye Clinic
- Cook County Health & Hospitals System
- Illinois Retina Associate
- Raj K.Maturi, MD
- University of Kansas School of Medicine
- Cumberland Valley Retina Consultants
- Ophthalmic Consultants of Boston
- Kresge Eye Institute
- Associated Retina Consultants-Royal Oak
- Discover Vision Center
- Eye Associates of New Mexico
- New York Eye & Ear Infirmary of Mt. Sinai
- Wake Forest Baptist Medical Center/Surgery
- Cleveland Clinic Cole Eye Institute
- Cascade Medical Research Institute, LLC
- Retina Vitreous Consultants
- Mid Atlantic Retina
- UPMC Eye Center
- Vanderbilt Eye Institute
- Austin Retina Associate
- Texas Retina Associates-Dallas-Main
- Houston Eye Associates
- Retina Consultants of Houston
- Valley Retina Institute
- Foresight Studies, San Antonio
- Medical Center Ophthalmology Associate
- Retina Group of Washington
- West Virginia University Eye Institute
- Centro De Ojos Loria SRL
- Clinica Privada de Ojos
- Primer Hospital Privado De Ojos
- Hospital Universitario Austral
- Gustavo Ariel Budmann Private Office
- Oftalmologia Global
- Organización Médica de Investigación (OMI)
- Centro Privado de Ojos Romagosa Fundacion VER
- Sri Sankaradeva Nethralaya
- Banker's Retina Clinic & Laser Centre
- Narayana Nethralaya
- Disha Eye Hospitals Pvt Ltd
- PBMA'S H. V. Desai Eye Hospital
- LV Prasad Eye Institute
- SMS Hospital
- Sankara Nethralaya
- Aravind Eye Hospitals
- Aravind Eye Hospital (Coimbatore)
- L V Prasad Eye Institute
- Dr. J.L. Rohatgi Memorial Eye Hospital
- BB Eye Foundation
- Advanced Eye Center
- Polo Universita degli Studi di Milano Ospedale Luigi Sacco Clinca Oculistica (Eye Clinic)
- Universita degli Studi di Padova - Azienda Ospedaliera di Padova - Clinica Oculistica
- A.O.U. Policlinico SantOrsola-Malpigi
- San Raffaele Scientific Institute
- Azienda USL IRCCS Reggio Emilia
Arms of the Study
Arm 1
Arm 2
Arm 3
Experimental
Sham Comparator
Other
Test Arm: DE-109 Injectable Solution
Control Arm: Sham Procedure
Dummy Arm: DE-109 Injectable Solution
Intravitreal injection of DE-109 440 µg in the study eye(s) every 2 months (Day 1, Month 2, and Month 4) (approximately 80 subjects).
Sham procedure administered to the study eye(s) every 2 months (Day 1, Month 2, and Month 4) (approximately 80 subjects). The sham procedure mimics an intravitreal injection without penetrating the eye.
Dummy Arm: Intravitreal injection of DE-109 at an undisclosed, fixed dose (within the range of 44 µg to 880 µg) in the study eye(s) every 2 months (Day 1, Month 2, and Month 4) (approximately 40 subjects). This study arm (which has the same route of administration and frequency as the test arm).